IGF1R and cancer: The IGF-1R is a highly cancer relevant RTK, explored extensively in anti-cancer therapeutic approaches [18–21], all aiming to inhibit receptor kinase activity either by preventing ligand–receptor interaction (e.g. blocking antibodies) or mitigating the effects of this interaction (e.g. tyrosine kinase inhibitors (TKIs)).